Overview: Newborn Screening 2 Panel
Introduction: The Newborn Screening 2 Panel is a diagnostic tool designed to screen for newborn metabolic disorders using whole blood samples. In India, congenital hypothyroidism (CH) and G6PD deficiency are among the most common screened conditions, with CH prevalence ~1 in 1,000â€"2,000 births (higher in iodine-deficient areas) and G6PD deficiency ~3-15 percent in males (higher in tribal populations), leading to preventable intellectual disability, kernicterus, or hemolytic crises if untreated. High morbidity from under-screening in rural/low-SES deliveries (home births, limited NBS programs), delayed diagnosis/treatment causing irreversible brain damage or neonatal mortality. Per pediatrics practices aligned with ICMR, National Health Mission, and Rashtriya Bal Swasthya Karyakram (RBSK) guidelines, the test employs PCR for G6PD deficiency and TSH over 1-2 days with high accuracy, valuable as basic expanded NBS in resource-limited settings. This diagnostic falls under newborn screening and targets all newborns (ideally 48-72 hours post-birth), addressing accurate detection to guide levothyroxine for CH or phototherapy/avoidance of triggers for G6PD. With elevated morbidity due to under-screening, the test supports public health efforts by enabling early intervention and reducing preventable disability burden. Its whole blood-based approach ensures reliable genetic/hormonal detection.
Other Names: NBS 2 Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: TSH/G6PD basic NBS expanded in India since 2010s under RBSK.
Purpose: The test assesses 2 parameters including G6PD deficiency to guide newborn metabolic screening, detect treatable disorders, inform early therapy.
Test Parameters: 1. G6PD Deficiency, 2. TSH.
Pretest Condition: No fasting required; newborns 48-72 hours old preferred.
Specimen: 3 mL whole blood in 1 EDTA tube (heel prick preferred), transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve DNA/hormone integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Parents should provide details on family history of jaundice, thyroid disease.
Consent: Written parental informed consent is required, detailing the test's purpose, potential risks of untreated disorders including disability, benefits of screening, and minimal discomfort from heel prick.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or prematurity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal TSH indicates CH; G6PD deficiency flags hemolytic risk, necessitating specialist input.
Specialist Consultation: Pediatric endocrinologists or neonatologists should be consulted for management.
Additional Supporting Tests: Serum TSH/FT4, G6PD enzyme assay for confirmation.
Test Limitations: Basic panel only; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, NBS Studies India 2023.
